This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications. In December 2020, we made minor changes to the ...
Diabetes Mellitus, Type 2/drug therapy,
Diabetes Mellitus, Type 2/prevention & control,
Patient Education as Topic,
Glucose/analysis,
Eye-Tracking Technology,
Dipeptidyl-Peptidase IV Inhibitors/therapeutic use,
Pioglitazone/therapeutic use,
Sulfonylurea Compounds/therapeutic use,
Platelet Aggregation Inhibitors/therapeutic use
This guideline covers the assessment and early management of head injury in children, young people and adults. It promotes effective clinical assessment so that people receive the right care for the severity of their head injury, including referral directly to specialist care if needed. In September 2019...
Macle, L;
Cairns, J;
Leblanc, K;
Tsang, T;
Skanes, A;
Cox, JL;
Healey, JS;
Bell, A;
Pilote, L;
Andrade, JG;
Mitchell, LB;
Atzema, C;
Gladstone, D;
Sharma, M;
Verma, S;
Connolly, S;
Dorian, P;
Parkash, R;
Talajic, M;
Nattel, S;
Verma, A.
The Canadian Cardiovascular Society (CCS) Atrial Fibrillation (AF) Guidelines Committee provides periodic reviews of new data to produce focused updates that address clinically important advances in AF management. This 2016 Focused Update deals with: (1) the management of antithrombotic therapy for AF pa...
Anticoagulants,
Cardiotonic Agents,
Platelet Aggregation Inhibitors,
Digoxin,
Magnesium,
Acute Coronary Syndrome/therapy,
Algorithms,
Anticoagulants/therapeutic use,
Atrial Appendage/surgery,
Atrial Fibrillation,
Cardiac Pacing, Artificial,
Cardiotonic Agents/adverse effects,
Catheter Ablation,
Cardiotonic Agents/administration & dosage,
Atrial Fibrillation/therapy,
Atrial Fibrillation/complications,
Hemorrhage/chemically induced,
Hemorrhage/prevention & control,
Magnesium/therapeutic use,
Percutaneous Coronary Intervention,
Platelet Aggregation Inhibitors/therapeutic use,
Postoperative Complications/prevention & control,
ST Elevation Myocardial Infarction/therapy,
Stroke/prevention & control,
Coronary Artery Disease/complications,
Digoxin/administration & dosage,
Digoxin/adverse effects,
Drug Therapy, Combination,
Factor Xa Inhibitors/therapeutic use,
Fibrinolytic Agents/therapeutic use,
Factor Xa Inhibitors
This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It
focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose
levels, and identifying and managing long-term complications....
Rutter, M. D;
Chattree, A;
Barbour, J. A;
Thomas-Gibson, S;
Bhandari, P;
Saunders, B. P;
Veitch, A. M;
Anderson, J;
Rembacken, B. J;
Loughrey, M. B;
Pullan, R;
Garrett, W. V;
Lewis, G;
Dolwani, S.
These guidelines provide an evidence-based framework for the management of patients with large non-pedunculated colorectal polyps (LNPCPs), in addition to identifying key performance indicators (KPIs) that permit the audit of quality outcomes. These are areas not previously covered by British Society of ...
This guideline covers the care and treatment of people with, or at risk of developing, chronic kidney disease. It aims to prevent or delay the progression of chronic kidney disease, reduce or prevent the development of complications, and reduce the risk of cardiovascular disease....
La finalidad de esta guía es proporcionar unas recomendaciones para el uso de Inhibidores de la Bomba de Protones (IBP), tanto en el ámbito de la atención primaria como en el de atención especializada. Su objetivo principal es dar a conocer las indicaciones de los IBP en prevención primaria de event...
